Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Buscar Study Connect
Ícono de BMS, studio Reclutando

Recruiting

ID del estudio CA247-0004  |   NCT05578092

A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

Resumen

  • Phase 1/Phase 2
  • Ícono de género masculino y femenino
  • 18+
  • 12
  • Ícono de BMS, studio Reclutando
    Recruiting

Descripción general

This is a Phase 1/2, open-label, multicenter, study evaluating the safety, tolerability, PK, PD, and anti-tumor activity of MRTX0902 alone and in combination with MRTX849 (adagrasib) in patients with advanced solid tumor malignancy harboring mutations in the KRAS-MAPK pathways.

Imprimir Imprimir
Email Correo electrónico

Centro de reclutamiento más cercano

Criterios clave de elegibilidad

Criterios de inclusión

Criterios de inclusión Icon
:
  • Histologically confirmed diagnosis of a solid tumor malignancy with any of the following oncogenic mutations detected in tumor tissue or ctDNA by a sponsor-approved test: 1. MRTX0902 monotherapy: known KRAS mutations, known annotated recurrent activating SOS1, PTPN11, class III BRAF, or EGFR mutation, or known annotated recurrent inactivating NF1 mutation; 2. MRTX0902 and adagrasib combination therapy: KRAS G12C mutation.
    1. Unresectable or metastatic disease
      1. No available treatment with curative intent; standard treatment is not available or patient declines
        1. Presence of tumor lesions to be evaluated per RECIST 1.1: 1. Phase 1 dose escalation, RECIST 1.1 measurable or evaluable disease 2. Phase 1b and Phase 2 cohorts, RECIST 1.1 measurable disease
          1. Presence of a tumor lesion amenable to mandatory biopsy for pharmacodynamic evaluation at baseline and on-study unless Sponsor-confirmed as medically unsafe or infeasible.
            1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
              1. Adequate organ function

                Criterios de exclusión

                Criterios de exclusión Icon
                :
                • Active brain metastases or carcinomatous meningitis
                  1. Prior treatment with a KRAS G12C inhibitor (for Phase 1b expansion for MRTX0902 and adagrasib combination, and Phase 2 cohorts only)
                    1. History of significant hemoptysis or hemorrhage within 4 weeks of the first dose of study treatment.
                      1. Major surgery within 4 weeks of first dose of study treatment
                        1. History of pneumonitis or interstitial lung disease
                          1. Ongoing need for medication with following characteristics: substrate of CYP3A; strong inducer or inhibitor or CYP3A and/or P-gp; strong inhibitors of BRCP and proton pump inhibitors
                            1. Cardiac abnormalities
                              1. History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions (eg, uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study treatment or result in inability to swallow oral medications
                                Información Adicional *

                                Opciones de tratamiento

                                Brazos del estudio

                                INTERVENCIÓN ASIGNADA

                                Brazos del estudio

                                Experimental: Phase 1/1B Combination Therapy

                                INTERVENCIÓN ASIGNADA
                                • Drug: MRTX0902, MRTX849

                                Brazos del estudio

                                Experimental: Phase 1/1B Monotherapy

                                INTERVENCIÓN ASIGNADA
                                • Drug: MRTX0902

                                Brazos del estudio

                                Experimental: Phase 2

                                INTERVENCIÓN ASIGNADA
                                • Drug: MRTX0902, MRTX849
                                Dé el primer paso para ver si es compatible con un estudio clínico - Verifique su elegibilidad
                                Verifique su elegibilidad
                                Responda algunas preguntas sobre su salud para ver si puede ser compatible con este enstudio.
                                Compatibilizar con un estudio
                                Si es compatible, haga clic en el estudio para ver la lista de ubicaciones de los centros del estudio.
                                Seleccione una ubicación del centro del estudio
                                Seleccione una ubicación del centro del estudio que sea conveniente para usted
                                Registrarse
                                Proporcione sus datos de contacto para que el centro del estudio se comunique con usted.

                                Recomendamos encarecidamente que se comunique con BMS para informar los efectos secundarios (eventos adversos)
                                Los efectos secundarios (eventos adversos) y otros eventos reportables se definen aquí
                                Informe de efectos secundarios (eventos adversos) o quejas sobre la calidad del producto: información médica

                                ¿Tiene alguna pregunta? El soporte en vivo está disponible 24/7 - Llame 855-907-3286 o Envíenos un correo electrónico

                                ¿Tiene alguna pregunta? El soporte en vivo está disponible 24/7 -
                                Llame 855-907-3286 o Envíenos un correo electrónico